Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
KBRA Assigns Preliminary Ratings to BX 2025-LUNR
-
Gaza on the Brink: Action Against Hunger Races To Prevent Child Malnutrition
-
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025
-
AOC Remains the World's #1 Gaming Monitor Brand for the Sixth Year Running
-
Halliburton Announces Dividend
-
M-tron Industries, Inc. to Host Investor Presentation followed by Annual Meeting of Stockholders on June 10, 2025
-
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
-
Haivision to Announce Second Quarter Fiscal 2025 Financial Results on June 11, 2025
-
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
-
Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting
-
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
-
ROHM Develops Compact Surface-Mount Near-Infrared LEDs Featuring Industry-Leading Radiant Intensity
-
Erie’s Public Schools and Zurn Elkay Water Solutions Announce Donation for Cleaner, Healthier, Safer Drinking Water
-
Lynch Carpenter Investigates Claims in Marlboro-Chesterfield Pathology Data Breach
-
Servotronics Announces Important Development with the Annual Meeting of Shareholders
-
Lynch Carpenter Investigates Claims in Kettering Health Data Breach
-
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
-
Banco Comercial Português, S.A. informs about resolutions of the Annual General Meeting
-
Prospector Announces Final Closing of its Non-Brokered Private Placement to Fund Drilling on the ML Project, Yukon
-
Scott+Scott Attorneys at Law LLP Reminds Investors a Securities Action Has Been Filed Against Iovance Biotherapeutics, Inc. (IOVA)
-
Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025
-
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
-
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
-
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
-
Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients
-
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
-
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
-
Petrus Announces Results of Annual General Meeting of Shareholders
-
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
-
Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting
-
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annu
-
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Lyme Timber Receives the 2025 SFI Leadership in Conservation Award for Advancing Nature-Based Solutions in SFI-Certified Forests
-
Acceleware Ltd. Reports First Quarter 2025 Financial and Operating Results
-
Volastra Announces Initial Data from First-in-Human Phase I/II Trial of Novel KIF18A Inhibitor VLS-1488 to be Presented at 2025 ASCO Annual Meeting
-
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting
-
Taiho Oncology Presents Data at the 2025 American Society of Clinical Oncology Annual Meeting
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages BigBear.ai Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBAI
-
Boehringer Ingelheim Showcases Bold Vision for the Future of Cancer Care at ASCO 2025
-
West Fraser Releases 2024 Sustainability Report
-
Servier Presentations at ASCO 2025 Reinforce Company Leadership in IDH-Mutated Cancers
-
Foundation Medicine to Present Over 15 Abstracts at the 2025 ASCO® Annual Meeting
-
Vergent Bioscience Presents Phase 2B VISUALIZE Results Demonstrating Abenacianine for Injection (VGT-309) with Intraoperative Molecular Imaging Improved Tumor Visualization During Lung Surgery
-
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal A
-
D. Boral Capital acted as Exclusive Placement Agent to Luminar Technologies (NASDAQ:LAZR) in connection with its up to $200.0 Million Equity Linked Securities Offering
-
Cerrado Gold Announces First Quarter Financial Results Release Date and Conference Call
-
ImPact Biotech Announces Late-Breaking Podium Presentation at ASCO 2025 Highlighting ENLIGHTED Study Interim Analysis
-
City of Hope Researchers to Present Cancer Advances That Could Boost Survival at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO
